Merck to Acquire Curon Biopharmaceutical’s Novel B-Cell Therapy Drug for Potential $1.6 Billion
- August 16, 2024
Merck & Co. plans to buy Curon Biopharmaceutical’s next-generation B-cell therapy drug for certain cancers and autoimmune diseases in a deal valued at up to $1.6 billion, the companies announced August 9.
ARTICLE TAGS
You must be logged in to access this content.